Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report by Mark P Rogan & Karl Thomas
BioMed CentralJournal of Medical Case Reports
ssOpen AcceCase report
Fatal miliary Coccidioidomycosis in a patient receiving infliximab 
therapy: a case report
Mark P Rogan* and Karl Thomas
Address: Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Iowa Hospitals and Clinics, Iowa City, Iowa, 
USA
Email: Mark P Rogan* - mrogan@rcsi.ie; Karl Thomas - karl-thomas@uiowa.edu
* Corresponding author    
Abstract
A 78-year-old white male from Iowa in the United States of America receiving the anti- tumor
necrois factor (TNF) agent infliximab therapy for rheumatoid arthritis developed a cheek ulcer
which failed to respond to empiric antibiotic therapy. He subsequently presented with progressive
respiratory failure from miliary coccidioidomycosis which proved fatal. The patient vacationed in
Arizona 6 months previously and likely contracted the organism there as Iowa is not an endemic
area for coccidioidomycosis. Respiratory failure from miliary infiltration is an uncommon
presentation of coccidioidomycosis. Physicians should be aware of the importance of travel history
and potential for life-threatening coccidioidomycosis in patients receiving tumor necrosis factor
inhibitors.
Background
Tumour necrosis factor-α (TNF-α) is a cytokine that plays
an important role in inflammation. In pathophysiological
conditions, generation of TNF at high levels leads to the
development of inflammatory responses that are hall-
marks of many diseases. Anti- tumor necrosis factor agents
are being increasingly used for immunomodulation in a
wide variety of clinical conditions including inflamma-
tory bowel disease, arthritides, psoriasis and atopic der-
matitis. Early data suggests that they may have potential
roles in vasculitides [1] and possibly sarcoidosis [2]. It is
estimated that there are over 400,000 people currently on
anti- TNF-α therapies worldwide [3]. These agents
include: infliximab which is a chimeric mouse/human
monoclonal IgG1 antibody directed at TNF; etanercept:
which consists of 2 two copies of recombinant human
TNF receptor p75 attached to the Fc portion of IgG1 and
adalimumab-a fully human monoclonal antibody. Newer
anti- TNF-α agents such as CDP571, CDP870 and oner-
cept are currently being investigated in clinical trials [4].
Despite increasing popularity and broadening indications
for usage, the anti-TNF agents have been associated with a
wide variety of infections. We report a case of fatal miliary
coccidioidomycosis in a patient receiving infliximab ther-
apy.
Case Report
A 78-year-old white gentleman from Iowa was diagnosed
with sero-negative rheumatoid arthritis one year previ-
ously. He had been maintained on an immunosupressive
regime consisting of methotrexate and the anti-tumor
necrosis factor antibody, infliximab. A purified protein
derivative skin test placed prior to initiation of infliximab
was negative. His past medical history also included dia-
betes mellitus type II and hypertension. One-month prior
to admission, he developed a slowly enlarging right cheek
lesion (Figure 1). This was initially felt to be an area felt of
localized cellulitis. He was treated with seven days of
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lanate without any significant response.
He then presented to his local hospital with a 3-week his-
tory of progressive dyspnea on exertion, night sweats,
fevers and 8 lbs weight loss. He had a cough productive of
yellow mucoid sputum and was febrile to 38.5C. Investi-
gations performed at the local hospital included a com-
plete blood count that demonstrated a normochromic
normocytic anemia with a hemoglobin of 10.2 gm/µl. His
white blood cell count was elevated at 17,000 cells/L.
Atypical pneumonia serology was normal. A trans-
esophageal echo showed no vegetations. Blood and urine
cultures were negative. His chest x-ray demonstrated dif-
fuse bilateral infiltrates. A comuted tomography (CT) pul-
monary angiogram study was negative for pulmonary
embolus but demonstrated a diffuse, bilateral, miliary
interstitial infiltrate pattern (Figure 2). He was treated
empirically with levofloxacin and clindamycin for 7 days
but his respiratory status continued to decline and he was
transferred to the medical intensive care unit (MICU) at
our University hospital for further management.
On arrival at the MICU, he was in respiratory distress with
a respiratory rate of 32 breaths per minute. He was unable
to complete sentences. His oxygen saturations were 91%
on 80% oxygen by facemask and he was subsequently
intubated and ventilated. He had a high-grade fever of
40.5 C. He underwent punch biopsy of the ulcerated
papule on his right jaw-line. He also had bronchoscopy
via the endotracheal tube. Bronchoscopy revealed normal
appearing mucosa with widely patent airways and no sig-
nificant secretions. Bronchoalveolar lavage (BAL) was per-
formed times 2 with 20 mls per lavage with good return
from the right middle lobe. Hematoxylin and eosin stain-
ing of both the cheek punch biopsy and the BAL revealed
thick walled spherules containing endospores consistent
with Coccidioides (figure 3). The patient was commenced
on liposomal amphotericin (1.0 mg/kg per day) but
despite this treatment, the patient ultimately died from
respiratory failure 2 weeks later. On review of his travel
history, the patient had lived in the mid-west all his life.
However, 6 months prior to the onset of this illness, he
spent 2 weeks visiting relatives in Phoenix, Arizona.
Discussion
Coccidioidomycosis is a fungal disease caused by 2 nearly
identical species, Coccidioides immitis and C. posadasii. It is
endemic to areas of southwestern USA known as the
Lower Sonora Life Zone. This semiarid zone encompasses
The patient's CT demonstrating bilateral, miliary interstitial infiltrate patternFigure 2
The patient's CT demonstrating bilateral, miliary interstitial 
infiltrate pattern.
The ulcerated papule on the patient's right cheek with a close up view of the lesionFigure 1
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tral and southern California. Human infection occurs as a
result of inhalation of arthroconidia. The majority of peo-
ple exposed are asymptomatic but some develop an influ-
enza-like illness and occasionally pneumonia.
Dissemination is uncommon in immunocompetent hosts
[5,6].
Coccidioidomycosis is associated with skin lesions such
as the cheek lesion that our patient developed approxi-
mately 5-weeks prior to transfer to our ICU. We speculate
that he contracted coccidioidomycosis in Arizona and that
dissemination occurred over time whilst been treated with
infliximab. Cutaneous involvement occurs by haematog-
enous dissemination to the skin or, much more rarely,
from a primary cutaneous infection [7]. This lesion was
mistakenly thought to represent a localized area of cellu-
litis and the patient was empirically treated with antibiot-
ics for several weeks. Early biopsy and culture of this
lesion may have led to a prompt diagnosis of coccidioid-
omycosis and perhaps the fatal outcome could have been
prevented. This case highlights the consequences of a
delay in diagnosis in patients receiving anti-TNF thera-
pies.
Disseminated coccidioidomycosis has been previously
described in immunosuppressed patients. For example, it
is well recognized in the solid organ transplant popula-
tion where it is thought to be a result of a primary infec-
tion or reactivation of latent infection [8]. Other groups of
patients at risk for dissemination include pregnant
women, African Americans and Filipinos, diabetics, HIV-
positive patients and patients with lymphoma and other
forms of immunosupression [7].
A recent meta-analysis of the anti-TNF antibody agents
infiximab and adalumimab in 3493 patients with rheu-
matoid arthritis demonstrated increased risk of serious
infections in 126 patients but only 1 case of coccidioid-
omycosis [9]. A multi-center study of rheumatologic
patients from coccidioidomycosis endemic regions also
demonstrated increased risk of coccidioidomycosis in
patients treated with TNF antagonists [10]. In this study,
13 cases of coccidioidomycosis (12 associated with inflix-
imab and 1 with etanercept) were identified among 918
patients being treated with TNF antagonist over a 5-year
period. Interestingly, all patients presented with lobar
pneumonia. None of the patients in this study had the
bilateral, miliary infiltrates and progressive respiratory
failure that we describe in this case. Only 5 patients were
hospitalized: 2 died – one from meningeal coccidioid-
omycosis and one from central venous catheter related-
sepsis.
In summary, anti TNF-α therapy is becoming more wide-
spread in clinical use. These agents may predispose to dis-
seminated, deep fungal infection and tuberculosis.
Current recommendations prior to anti-TNF-α therapy
include a chest x-ray, a tuberculin skin test and coccidio-
idomycosis serology. However serology may be an unreli-
able indicator of disease in such patients [5,10].
Coccidioidomycosis is one of the great imitators and may
be the etiology of serous cavity infections such as pericar-
ditis, empyema and peritonitis. It should be considered in
the differential among patients presenting with atypical
infections and a history of exposure to an endemic area. A
careful travel history should be obtained in all patients
prior to commencing anti TNF therapy. Physicians should
maintain a high level of vigilance and promptly investi-
gate any new signs or symptoms such as skin lesions in
these patients. Antifungal prophylaxis with azole therapy
is currently recommended for some high risk patients
undergoing organ transplant from endemic areas [8].
Azole prophylaxis may have a role in patients on anti
TNF-α therapy that live in endemic areas. In our case, the
patient visited an endemic area for a brief period and then
developed fatal coccidioidomycosis 6-months later. Fur-
ther studies regarding the incidence of coccidioidomyco-
sis in patients on anti TNF-α therapies and the
effectiveness of azole prophylaxis in this group are needed
before definitive recommendations can be made.
Conclusion
We describe a case of fatal miliary coccidioidomycosis in
a 78 year old white man taking the anti-TNF agent inflixi-
mab. The patient had vacationed briefly in an endemic
area 6 months prior to presentation. He presented with a
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Hematoxylin and eosin staining of the skin biopsy (50x) dem-
onstrating thick walled spherules containing endospores 
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cheek lesion and rapidly progressive miliary lung infiltra-
tion and ultimately died from respiratory failure. This case
highlights the importance of a travel history and the need
for prompt investigation and diagnosis of cutaneous
lesions in this patient population.
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